DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for beta thalassemia — screening already-approved drugs against its 15-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBeta thalassemia maps to a 15-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedHydroxyureaApproved drug
Structures already discussed alongside beta thalassemia in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Periplasmic portion of the Helicobacter pylori chemoreceptor TlpB — Hydroxyurea has a real, experimentally solved structure in complex with this target (PDB 3UB9, 1.42 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet nhydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3UB9 · 1.42 Å · ligand Hydroxyurea (NHY). Experimental structure, not a prediction.
What the evidence adds up to
A 2008 study from Iran reported that 19 out of 207 beta thalassaemia patients (9.2%) were drug dependent, a prevalence close to the 10.2% seen in the general population of Fars province and the 12.5% national rate. The most common motivation given was enjoyment. Statistically significant risk factors were male sex, being single, having a surgical history, and a family history of drug addiction. The authors noted this was the first study worldwide on the topic and called for more work to improve patients’ quality of life.
A 2025 study measured expression of the immune checkpoints LAG-3, CTLA-4, TIM-3 and PD-1 in beta thalassaemia patients treated either with regular blood transfusions (n=33) or with HbF-augmenting drugs such as hydroxyurea and thalidomide (n=140), compared with 27 healthy controls. LAG-3 expression was increased in all patients regardless of treatment. CTLA-4 was higher specifically in the transfusion group. TIM-3 and PD-1 were higher in patients on HbF-augmenting drugs than in either transfused patients or controls. Correlation between serum ferritin and any immune checkpoint was very weak to absent. The authors concluded that the altered immune regulation could be due to thalassaemia itself, repeated blood product exposure, recurrent infections, or the immunomodulatory effects of drugs like thalidomide.
A 2019 book on beta thalassaemia covered pathogenesis, genetics, diagnosis, and both standard and novel therapies, but provided no new trial data or quantitative results. It aimed to summarise current practice and future possibilities.
What is still missing are prospective studies linking immune checkpoint changes to clinical outcomes such as infection rates or transfusion burden, larger and more diverse patient cohorts, and trials designed to separate the effects of the disease from those of its treatments. The 2008 addiction study is now nearly two decades old and has not been replicated. No study has yet shown that modulating immune checkpoints improves survival or reduces transfusion dependence.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
IntechOpen eBooks · 2019 · 2 citations
Beta Thalassemia
AbstractBeta thalassemia is a common blood disorder worldwide. Thousands of infants with beta thalassemia are born each year. This book covers most of the aspects related to this disease and greatly helps in understanding this disease and its complications. Of interest are clinical studies as well as basic and translational research reports regarding pathogenesis, genetics, diagnosis as well as standard and novel therapies. This book intends to provide the reader with a comprehensive overview of today's practices and tomorrow's possibilities about beta thalassemia.
Turkish Journal of Hematology · 2025 · 1 citations · open access
Expression of Immune Checkpoints LAG-3, CTLA-4, TIM-3 and PD-1 in Beta Thalassemia patients Treated using HbF Augmentation Therapy and Regular Transfusions
AbstractIntroduction: Beta-thalassemia is an inherited hemoglobin disorder caused by mutations in HBB gene encoding beta globin chains.Severe anemia secondary to defective globin chains, chronic hemolysis and ineffective erythropoiesis requires transfusion support from early childhood.Recently used treatment options with promising results in resource limited countries includes drugs which augment HbF such as hydroxyurea and thalidomide.Although effective in alleviating anemia and related symptoms, these drugs particularly thalidomide has been known for its immunomodulatory role.Similarly, repeated transfusions with compromised immune system increases the risk of infections and weakened immunity.One of the key regulators of immune systems includes immune checkpoints, cell surface molecules on immune cells.Limited studies are available on immune checkpoints such as LAG-3, CTLA-4, TIM-3 and PD-1 expression in thalassemia and its treatment.Objectives: This study aimed to compare LAG-3, CTLA-4, TIM-3, and PD-1 expression in patients treated using HbF augmenting drugs or transfusions and with iron overload.These findings will provide an insight into the immune regulation in betathalassemia in response to treatment.Methods: In this study, the expression of LAG-3, CTLA-4, TIM-3 and PD-1 was quantified using real time PCR in patients managed on blood transfusions (n=33) or HbF augmenting drugs (n=140) and compared with healthy controls (n=27).Results: Our results show an increased expression of LAG-3 in patients regardless of treatment whereas increased CTLA-4 in patients on regular transfusions.On the other hand, the expressions of TIM-3 and PD-1 were higher in patients taking HbF augmentation therapy compared to patients on blood transfusions or the healthy controls.A very weak to no correlation was found between serum ferritin and immune checkpoints.Conclusions: These findings are suggestive of alterations in immune regulation in betathalassemia which could be attributed to thalassemia itself, repeated exposure to blood products, recurrent infections and the immunomodulatory drugs.
Evaluation of prevalence of drug dependence in beta‐thalassemic patients and its risk factors
AbstractObjective: Beta thalassemia is a hereditary disease of hemoglobin synthesis that causes mild to severe microcytic anemia and hemosiderosis in many organs that in severe cases results in organ failure. Many of the patients need blood transfusions. Drug dependence is a recurrent and chronic problem that has both physiological and behavioral aspects.Methods and materials: A total of 207 β thalassemic patients were randomly assigned out of 810 β thalassemic patients that referred to Shiraz Coolys Center in May–July 2005 in the south of Iran. We studied the prevalence of addiction in these patients and compared this with the normal population. We also evaluated the probable risk factors of drug dependence. There was no other study found worldwide at this time.Results: Of these 207 patients, 19 (9.2%) patients were drug dependent and their most common motivation was acquisition of enjoyment. Among the several risk factors that were studied, sex (male), marital status (single), surgical history and family drug addiction history were found to be statistically significant (0.01<p value <0.05).Discussion: Although the prevalence of addiction in thalassemic patients (9.2%) was nearly the same in the normal population of Fars province (10.2%) and Iran (12.5%), it still has a high prevalence and it should be considered as a psychical‐social problem. As this study was the first one done regarding this topic, we hope that in the future more studies will be conducted to help these patients to have a better lifestyle and improve life expectancy and quality of life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
